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ABSTRACT. Genetic prion diseases are degenerative brain disorders caused by mutations in the
gene encoding the prion protein (PrP). Different PrP mutations cause different diseases, including
Creutzfeldt-Jakob disease (CJD), Gerstmann-Str€aussler-Scheinker (GSS) syndrome and fatal familial
insomnia (FFI). The reason for this variability is not known. It has been suggested that prion strains
with unique self-replicating and neurotoxic properties emerge spontaneously in individuals carrying
PrP mutations, dictating the phenotypic expression of disease. We generated transgenic mice
expressing the FFI mutation, and found that they developed a fatal neurological illness highly
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reminiscent of FFI, and different from those of similarly generated mice modeling genetic CJD and
GSS. Thus transgenic mice recapitulate the phenotypic differences seen in humans. The mutant PrPs
expressed in these mice are misfolded but unable to self-replicate. They accumulate in different
compartments of the neuronal secretory pathway, impairing the membrane delivery of ion channels
essential for neuronal function. Our results indicate that conversion of mutant PrP into an infectious
isoform is not required for pathogenesis, and suggest that the phenotypic variability may be due to
different effects of mutant PrP on intracellular transport.
KEYWORDS. Genetic prion disease, fatal familial insomnia, Creutzfeldt-Jakob disease,
Gerstmann-Str€aussler-Scheinker syndrome, PrPC, PrPSc, transgenic mice, sleep, membrane
trafficking, protein misfolding
INTRODUCTION
Genetic prion diseases are dominantly inher-
ited neurodegenerative disorders linked to
mutations in the PRNP gene encoding the cel-
lular prion protein (PrPC), on chromosome 20.
More than 60 pathogenic PRNP variants have
been reported, including missense mutations
that lead to single amino acid substitutions,
expansions or deletions of a repeated sequence
encoding an octapeptide motif in the N-termi-
nal region, and stop codon mutations resulting
in premature protein truncations (Fig. 1).
One striking feature of genetic prion diseases
is their phenotypic heterogeneity. Different
PRNP mutations are associated with distinct
clinical and neuropathological phenotypes:
genetic Creutzfeldt-Jakob disease (gCJD), fatal
familial insomnia (FFI), Gerstmann-Str€aussler-
Scheinker (GSS) syndrome, PrP cerebral amy-
loid angiopathy (PrP-CAA) and PrP systemic
amyloidosis.1,2 The disease presentation can be
influenced by PRNP polymorphism at codon
129, where either methionine (M) or valine (V)
may be present. A noteworthy example is the
prion disease linked to the substitution of aspar-
agine (N) for aspartic acid (D) at codon 178
which, depending on the aminoacid at codon
129 on the mutant allele, segregates with either
FFI (D178N/M129), primarily characterized by
severe sleep disorders and autonomic dysfunc-
tion, or CJD178 (D178N/V129), clinically iden-
tified by global cortical dementia and motor
abnormalities.
How sequence variants of PRNP encode the
information to specify distinct disease pheno-
types is a central question in prion biology. The
pathogenic mutations favor PrPC misfolding,
eventually leading to the formation of a deter-
gent-insoluble, proteinase-K (PK)-resistant iso-
form (PrPSc or prion) which propagates by
imprinting its abnormal conformation onto
native PrPC molecules.3 Brain tissues from dif-
ferent genetic prion disease patients contain
protease-resistant PrP isoforms with distinct
PK cleavage sites, consistent with their differ-
ent conformations. When laboratory animals
are inoculated intracerebrally with brain homo-
genates from these patients, they accumulate
PrPSc molecules with the same PK resistant
core as the inoculated PrP, and develop neuro-
logical diseases with different incubation times
and neuropathological lesions.4 Thus, different
mutant PrPs can give rise to conformational
variants of PrPSc (prion strains) which can be
propagated in laboratory animals, causing dis-
tinct brain pathologies.
However, some genetic prion diseases
develop in the virtual absence of biochemically
detectable PrPSc, or in the presence of other
abnormal forms of PrP, and are difficult to
transmit or nontransmissible to laboratory ani-
mals.2,5 This suggests that mutant PrP has neu-
rotoxic properties that are independent of its
ability to self-replicate and that pathogenic
mechanisms unrelated to prion strain propaga-
tion may govern disease manifestation in car-
riers of PRNP mutations.
To investigate the mechanisms of mutant
PrP neurotoxicity, and specifically the role of
the M/V 129 polymorphism in directing the
disease phenotype, we developed transgenic
(Tg) mouse models of CJD178 and FFI. We
previously reported that Tg(CJD) mice,
94 R. Chiesa et al.
expressing the mouse PrP (moPrP) homolog
of human PrP D178N/V129 (moPrP D177N/
V128), closely reproduce essential features of
CJD178.6 More recently, we have generated
Tg(FFI) mice expressing moPrP D177N/
M128, and found that they develop a fatal
neurological disease different from that of Tg
(CJD) mice and highly reminiscent of FFI.7
Comparative analysis of these models, and
similarly generated Tg(PG14) mice carrying
a octapeptide repeat expansion associated
with GSS,8 indicate prion infectivity-indepen-
dent mechanisms of pathogenesis and pheno-
typic expression of disease.
A TRANSGENIC MOUSE MODEL OF
FFI
FFI was described in 1986 by Elio Lugaresi
and coworkers in a 53-year-old Italian man
brought to their attention by Ignazio Roiter, a
physician who had been investigating a “peculiar
fatal disorder of sleep” which had run in his
spouse’s family since the middle of the 19th cen-
tury.9 In addition to the large FFI kindred identi-
fied by Roiter (reported in Cortelli et al.10),
families with the FFI mutation were later found
in Italy andmany countries worldwide, including
France, Germany, Austria, UK, USA, Australia,
Japan and China. The FFI mutation has a high
penetrance11—more than 90% of the carriers
will develop the disease, which usually manifests
in the fifth decade of life. Analysis of 46 cases
belonging to the Italian kindred indicated that the
risk of developing FFI is highest between 50 and
55 y of age.12 So far only 2 carriers in this kin-
dred reached old age (>75 years) without devel-
oping FFI (I. Roiter, personal communication).
Disruption of sleep is the most striking clini-
cal feature of FFI.13 It begins with the inability
to initiate and maintain sleep. As the disease
FIGURE 1. Schematic representation of the human PrP structure, with polymorphisms and report-
edly pathogenic PRNP variants. The human (hu) PrP 1–253 structure is depicted with polymor-
phisms and post-translational modifications indicated above, and reportedly pathogenic mutations
below. In the mature protein (huPrP 23–230) the N-terminal signal peptide (1–22) and the C-termi-
nal signal (231–253) for attachment of the glycosyl-phosphatidyl-inositol (GPI) anchor are
removed. Region 51–91 containing one nonapeptide and 4 octapeptides is in yellow; b-sheet
regions (b1 128–131 and b2 161–164) are in black and a-helices (a1 144–154, a2 173–194 and a3
200–228) are in green. S-S, disulphide bond between aminoacids 179 and 214; CHO, N-glycosyla-
tion sites at positions 181 and 197. All mutations are associated with a CJD phenotype except
those in bold type (GSS), solid box (FFI or CJD depending on codon 129 genotype), dotted box
(frontotemporal lobar degeneration-like phenotype), solid underlined (PrP-CAA), dash underlined
(peripheral PrP amyloidosis with PrP-CAA), gray (sensory neuropathy) and blue (unclassified phe-
notype). The octapeptide repeat insertions produce variable phenotypes, including CJD, GSS- and
frontotemporal dementia-like syndromes.
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progresses patients become sleep deprived,
somnolent and apathetic, and experience onei-
ric behaviors—peculiar hallucinatory states
during which they display motor gestures
related to the content of a dream. Longitudinal
24 h electroencephalography (EEG) shows an
early and progressive reduction of sleep spin-
dles and K complexes (2 EEG waveforms typi-
cal of sleep without rapid eye movements or
NREM sleep), severe reduction of total sleep
time, sleep fragmentation and profound disrup-
tion of its cyclic organization. Deep-sleep
stages and slow-wave activity (SWA, a mea-
sure of sleep drive and depth) are largely lost,
and patients enter a subwakefulness state inter-
rupted by episodes of rapid eye movement
(REM) sleep which are behaviorally linked
with dream enactment.13 The loss of sleep is
associated with increased motor activity and
loss of 24 h circadian motor rhythm. Patients
also present progressive increases in heart and
breathing rates, systemic arterial pressure, and
core body temperature, indicative of sympa-
thetic hyperactivity. Death usually occurs
within 2 y from the initial clinical signs, with
individuals carrying M at codon 129 on the
wild-type (WT) PRNP allele (M/M129 homo-
zygotes) having a shorter course than M/V129
heterozygotes.13 Neuropathological examina-
tion at autopsy shows predominant degenera-
tion of the anterior ventral and mediodorsal
nuclei of the thalamus, with variable involve-
ment of the cerebral cortex and cerebellum,
and moderate astrogliosis. The brains of FFI
patients contain small amounts of PK-resistant
PrP, which has an apparent molecular mass of
19 kDa after deglycosylation. Widespread PK-
resistant PrP deposits can be detected by immu-
nohistochemistry, especially in the cases of
long duration.14
We produced Tg(FFI) mice using the experi-
mental strategy previously used to generate Tg
(CJD) and Tg(PG14) mice.6,8 The cDNA
encoding moPrP D177N/M128 was cloned into
the MoPrP.Xho transgenic vector (also known
as half genomic PrP) which contains a 12 kb
fragment of the moPrP gene (Prnp), including
the promoter and intron 1, and drives the
expression of transgenic PrP with a tissue pat-
tern similar to that of endogenous moPrP.6 The
transgene was injected into the pronuclei of fer-
tilized eggs from an F2 cross of C57BL/6J x
CBA/J F1 parental mice.
In a first set of experiments, we used a ver-
sion of moPrP D177N/M128 in which leucine
108 and valine 111 were replaced with methio-
nine residues. This generates the epitope for
monoclonal antibody 3F4, which is normally
found in hamster and human but not in mouse
PrP, and which we used in our previous Tg
models to distinguish transgenic from endoge-
nous moPrP.6,8 However, since the 3F4 epitope
makes moPrP less prone to prion-induced con-
version,15-17 we reasoned that it could hamper
spontaneous conversion of mutant PrP to infec-
tious PrPSc; therefore we also constructed Tg
(FFI) mice expressing untagged PrP. The Tg
founders were backcrossed for > 9 generations
with an inbred colony of C57BL/6J/Prnp0/0
(PrP knockout, KO) mice, so they expressed
mutant but not endogenous wild-type PrP and
had a homogeneous genetic background.7 Par-
allel with the Tg(FFI) mice, we also produced
new lines of Tg(CJD) mice expressing
untagged moPrP D177N/V128.7 These mice
synthesized detergent-insoluble, protease-resis-
tant PrP molecules in their brains, and devel-
oped a neurological disease indistinguishable
from that previously described in Tg(CJD)
mice expressing 3F4-tagged mutant PrP.6
Tg(FFI) mice expressing mutant PrP at phys-
iological levels developed mild neurological
signs and lived as long as nontransgenic con-
trols, consistent with previous observations in
knockin mice in which 3F4-tagged moPrP
D177/M128 was expressed from the endoge-
nous Prnp locus.17 In contrast, Tg(FFI) mice
expressing mutant PrP at twice the endogenous
level or more developed a progressive and
invariably fatal neurological disease, and accu-
mulated detergent-insoluble, protease-resistant
PrP in their brains, yielding a 19 kDa C-termi-
nal fragment after mild PK digestion and degly-
cosylation, like in FFI patients.7
Tg(FFI) mice had profound sleep alterations
reminiscent of those seen in human FFI.7 Lon-
gitudinal 24h monitoring and spectral EEG
analysis showed a marked reduction of sleep
spindle density compared to nontransgenic
mice (Fig. 2A). SWA during NREM sleep was
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significantly reduced in Tg(FFI) mice
(Fig. 2B). The mutant mice also presented a
profound disruption of sleep continuity and
organization. They had a larger number of tran-
sitions between the different behavioral states
(wake, REM and NREM sleep) than controls
(Fig. 3A), indicating broken, non-restorative
sleep. In addition, in Tg(FFI) mice approxi-
mately a quarter of REM sleep episodes started
directly from wakefulness, instead of being
preceded by NREM sleep as normally occurs
(Fig. 3B). This was reminiscent of the
sudden-onset episodes of REM sleep that
intrude into wakefulness in FFI patients.
Like in FFI patients, the circadian organiza-
tion of sleep and motor activity was lost in Tg
(FFI) mice. Mice are nocturnal animals and
sleep about twice as much during the day as
during the night. Tg(FFI) mice slept only 50
percent more than controls (Fig. 4A). More-
over, compared to nontransgenic mice which
moved 3–4 times more during the night than
during the day, Tg(FFI) mice moved only about
1.5 times more (Fig. 4B).
Sleep-wake disturbances different from those
seen in FFI have been reported in sporadic CJD
and in CJD178 and are faithfully modeled by Tg
(CJD) mice.6,18 The alterations in sleep and cir-
cadian rhythm in Tg(FFI) mice differed signifi-
cantly from those in Tg(CJD) mice. Whereas in
Tg(FFI) mice the circadian organization of sleep
and motor activity was lost, sleep was
fragmented, and theta activity (the EEG hall-
mark of rodent REM sleep) was reduced,7 in Tg
(CJD) mice the circadian organization of sleep
and motor activity was preserved (Fig. 4), and
sleep continuity and its EEG patterns were not
altered.6,7 Thus Tg(FFI) and Tg(CJD) mice
recapitulated the specific sleep alterations of the
corresponding human diseases.
Other clinical symptoms of FFI include dysau-
tonomia, disturbances of attention and vigilance,
difficulties with the temporal ordering of events
and spatial disorientation, gait abnormalities,
ataxia and other motor deficits. Autonomic car-
diac control was altered in Tg(FFI) mice.19 They
were also impaired in recognition and spatial
working memory, and showed sensorimotor defi-
cits, abnormal gait and ataxia.7 Neuropathological
analyses indicated moderate gliosis and PK-resis-
tant PrP deposits in the thalamus and other brain
regions. MRI detected thalamic and cerebellar
atrophy.7 Thus, many salient aspects of human
FFI were recapitulated in transgenic mice.
SPONTANEOUS PRION GENERATION
IS NOT REQUIRED FOR
MANIFESTATION OF DISEASE IN
TRANSGENIC MICE
To answer the question whether prion
infectivity was generated de novo in the
FIGURE 2. Sleep spindles and slow-wave activity are reduced in Tg(FFI) mice. Number of sleep
spindles per hour (A) and normalized SWA during NREM sleep (B) were measured as described.7
Data are the mean § SEM of 8 non-Tg/PrnpC/C (WT), 10 non-Tg/Prnp0/0 (KO) and 9 Tg(FFI)/Prnp0/0
(FFI). **p < 0.01 by one-way ANOVA with Bonferroni’s correction.
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brains of Tg(FFI) and Tg(CJD) mice, 10%
brain homogenates from clinically ill mice
were inoculated intracerebrally into C57BL/
6J mice and Tga20 mice which overexpress
moPrP WT and are highly sensitive to prions.
Since homology between PrPSc in the inocu-
lum and PrPC in the recipient mice may
increase the chance of disease transmis-
sion,20,21 the brain homogenates from Tg
(FFI) and Tg(CJD) mice expressing 3F4-
tagged mutant PrP were also inoculated into
Tg(WT-E1) mice overexpressing 3F4-tagged
moPrP WT, and into Tg mice, which express
low levels of 3F4-tagged moPrP D177N and
do not spontaneously become ill.6,8 None of
the inoculated animals developed signs of
neurological disease and either died of inter-
current illnesses or were euthanized near the
end of their normal lifespan. Biochemical
analysis found no PrPSc in their brains.7
To test the possibility that Tg(FFI) and
Tg(CJD) brains contained prions below the
threshold of detection of our bioassay, the
brain homogenates were subjected to serial
protein misfolding cyclic amplification
(PMCA), which allows highly efficient
prion replication in vitro and can amplify
the equivalent of a single molecule of PrPSc.
No PrPSc was detectable in the PMCA reac-
tions by either biochemical analysis or bio-
assay in Tga20 mice.7 Thus the
manifestation of disease in Tg(FFI) and Tg
(CJD) mice was not associated with sponta-
neous prion formation. This was also the
case for Tg(PG14) mice,16 and other models
of GSS22,23 (J. A. Mastrianni, personal com-
munication), indicating that neurotoxic
mechanisms are operative in Tg mice that
produce different diseases independently of
prion generation and spread.
FIGURE 3. Sleep continuity and organization are affected in Tg(FFI) mice. (A) The number of tran-
sitions between wake, REM and NREM sleep, during the phases of the light-dark cycle were mea-
sured as described.7 Data are the mean § SEM of 8 non-Tg/PrnpC/C (WT), 10 non-Tg/Prnp0/0 (KO)
and 9 Tg(FFI)/Prnp0/0 (FFI). **p < 0.01 by mixed model for repeated measures followed by
between strains one-way ANOVA with Bonferroni’s correction. (B) Whereas a Tg(FFI)/Prnp0/0 (FFI)
mouse enters REM sleep directly from wakefulness (left arrow), as shown by the hypnogram (lower
trace), in a non-Tg/PrnpC/C (WT) mouse REM sleep is preceded by an episode of NREM sleep.
Top to bottom: EEG (electroencephalogram), EEG power in the delta (0.5 – 4 Hz, black line) and
theta (6 – 9 Hz, red line) bands, and the related hypnogram. Arrows indicate the beginning and end
of a REM sleep phase. Panel B is from ref. 7, Creative Commons Attribution (CC BY) license.
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POTENTIAL ROLE OF
INTRACELLULAR PrP
ACCUMULATION IN PHENOTYPIC
EXPRESSION OF DISEASE
The lack of prion infectivity in Tg(FFI), Tg
(CJD) and Tg(PG14) mice indicates that
conversion of the mutant PrPs into distinct
self-replicating PrPSc isoforms is not the
cause of phenotypic variation. What is it then
that produces different diseases in these mod-
els? Disease-specific features are seen in
independently generated lines of Tg(FFI), Tg
(CJD) and Tg(PG14) mice,6-8 strongly indi-
cating that they are encoded by the mutant
PrPs, rather than non-specific effects of ran-
dom transgenesis. Moreover, backcrossing
the different mutant mice to the same inbred
strain of C57BL/6J/Prnp0/0 mice ruled out
non-specific effects of mixed genetic back-
grounds or genetic drift.
Investigation of PrP metabolism and locali-
zation in primary neurons and transfected cells
showed that the PG14 and D177N mutants are
delayed in their biosynthetic maturation in the
endoplasmic reticulum (ER), and accumulate
abnormally in the secretory pathway,24,25 but
do not activate ER stress-related maladaptive
responses.26,27 PG14 and D177N/V128 PrPs
were mainly found in the ER, while D177N/
M128 localized preferentially to the Golgi.6,7
This may reflect differences in how these
mutants acquire abnormal conformations and
aggregate during secretory transport. There is
evidence, in fact, that PG14, D177N/V128 and
D177N/M128 PrPs differ in their monomeric
structures and states of aggregation,28 and
aggregation and intracellular retention are
closely related.29
In Tg(PG14) and Tg(CJD) mice, ER reten-
tion of mutant PrP impairs the synaptic delivery
of voltage-gated calcium channels (VGCCs)
through a physical interaction with the VGCC
a2-d subunit; this leads to reduced expression
of functional channels on the plasma mem-
brane, and defective cerebellar neurotransmis-
sion and motor control.30 We therefore
hypothesized that intracellular retention of
mutant PrP might affect the trafficking and
function of other PrPC-interacting ion channels,
and that mutants that tend to accumulate in dif-
ferent intracellular compartments might affect
trafficking in different ways, producing specific
neurotoxic effects.27,31
PrPC interacts physically with certain subu-
nits of N-methyl-D-aspartate (NMDA) and
a-amino-3-hydroxy-5-methyl-4-isoxazolepro-
pionic acid (AMPA) receptors, and these
FIGURE 4. Circadian organization of sleep and motor activity is lost in Tg(FFI) but not Tg(CJD)
mice. (A) Ratio of the total amounts of time animals spent asleep (NREM C REM) during the
phases of the light-dark cycle. (B) Ratio of the gross body movements made by the animals during
the phases of the light-dark cycle. Data were from 8 non-Tg/PrnpC/C (WT), 10 non-Tg/Prnp0/0 (KO),
9 Tg(FFI)/Prnp0/0 (FFI), and 9 Tg(CJD)/Prnp0/0 (CJD), as described.7 Data are the mean § SEM.
**p < 0.001 vs. WT and KO in A, and vs. KO in B; xp < 0.05 vs. WT in B; by one-way ANOVA, fol-
lowed by post-hoc Fisher’s least significant difference (LSD) test.
TRANSGENIC MICE RECAPITULATE PHENOTYPIC HETEROGENEITY 99
interactions are important for normal neuronal
physiology and survival.32,33 The assembly and
trafficking of these receptors are finely tuned in
the ER and Golgi. Our preliminary observa-
tions indicate that PG14, D177N/V128 and
D177N/M128 alter NMDA and AMPA recep-
tor trafficking in different ways. They also
interact differently with receptor subunit iso-
forms expressed in functionally distinct neu-
rons of the brain33 (and our unpublished
results). Thus PG14, D177N/V128 and D177N/
M128 may have different effects on the func-
tion and survival of different neurons—hence
on the clinical presentation of disease—
depending on where in the secretory pathway
they preferentially accumulate, and how this
interferes with the transport of the molecules
they interact with.
CONCLUDING REMARKS
A number of mouse models of genetic prion
disease have been generated, most of which
recapitulate specific features of the human dis-
orders without developing bona fide prions,6-
8,16,17,21-23,34-36 perhaps underscoring the diffi-
culty of reconstituting in short-lived animals a
molecular transformation that in humans may
take decades or not even occur. However, the
lack of infectivity does not invalidate these
models. In fact, it is an incidental advantage,
since it permits analysis of the primary patho-
genic consequences of mutant PrP misfolding
independently of toxic effects downstream of
PrPSc replication.
Our findings indicate a key pathogenic role of
PrP misfolding in the secretory pathway. By
accumulating intracellularly, the mutant PrPs
affect the trafficking of PrPC-interacting ion
channels, causing alterations in neurotransmis-
sion and behavioral abnormalities.30 Our prelim-
inary evidence indicates that different mutants
cause specific alterations of secretory transport,
suggesting a neurotoxic modality that may
explain the phenotypic heterogeneity of genetic
prion diseases.27 It is now important to identify
the molecules whose transport is disrupted by
the different mutants, to clarify how this leads to
selective neurotoxicity in animal models, and to
test whether the same mechanisms are operative
in humans. These important challenges will not
only cast light on the physiopathology of genetic
prion diseases but also help point the way to
devising targeted therapeutic approaches for
these devastating disorders.
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